Y-mAbs Therapeutics (YMAB) News Today $11.14 -0.45 (-3.88%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Y-mAbs: Strategic Partnership and Strong Financial Outlook Reinforce Buy RatingNovember 16 at 8:47 AM | markets.businessinsider.comY-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday.November 15 at 3:28 PM | marketbeat.comCantor Fitzgerald Issues Positive Estimate for YMAB EarningsNovember 15 at 1:13 AM | americanbankingnews.comCantor Fitzgerald Has Positive View of YMAB FY2024 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Y-mAbs Therapeutics in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earningsNovember 14 at 8:16 AM | marketbeat.comTruist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)November 12, 2024 | markets.businessinsider.comY-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comY-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, recently diNovember 11, 2024 | americanbankingnews.comY-Mabs Therapeutics Faces Uncertain Growth Amid Declining Danyelza Sales and Market ChallengesNovember 9, 2024 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPSY-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) announced its earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter last year, the company posted ($0.18) EPS.November 9, 2024 | marketbeat.comY-mAbs Reports Third Quarter 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comY-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67MNovember 9, 2024 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down - Here's WhyY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down - Here's WhyNovember 8, 2024 | marketbeat.comY-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsNovember 8, 2024 | globenewswire.comWhat To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 EarningsNovember 7, 2024 | finance.yahoo.comY-Mabs Therapeutics (YMAB) Gets a Buy from Truist FinancialNovember 5, 2024 | markets.businessinsider.comY-mAbs Partners with Nobelpharma for Japan ExpansionNovember 5, 2024 | markets.businessinsider.comY-mAbs, Nobelpharma announce exclusive license, distribution agreementNovember 5, 2024 | markets.businessinsider.comY-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in JapanNovember 4, 2024 | globenewswire.comOptimistic Buy Rating for Y-Mabs Therapeutics Driven by Innovative SADA PRIT Technology and Strategic AdvancementsNovember 1, 2024 | markets.businessinsider.comY-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on FridayY-mAbs Therapeutics (NASDAQ:YMAB) will be releasing earnings before the market opens on Friday, November 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640388)November 1, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating andOctober 27, 2024 | marketbeat.comY-mAbs Announces Third Quarter 2024 Conference Call and WebcastOctober 25, 2024 | globenewswire.comY-mAbs Therapeutics: Slow But Steady Prospect In Rare CancersOctober 21, 2024 | seekingalpha.comCubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Cubist Systematic Strategies LLC lessened its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 91.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,597 shares of the company's stock after selOctober 16, 2024 | marketbeat.comMillennium Management LLC Grows Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Millennium Management LLC raised its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 23.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 349,784 shares of the company's stock aOctober 13, 2024 | marketbeat.comMorgan Stanley Remains a Sell on Y-Mabs Therapeutics (YMAB)October 12, 2024 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.7% - Still a Buy?Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.7% - Here's WhyOctober 11, 2024 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...October 9, 2024 | finance.yahoo.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Dimensional Fund Advisors LPDimensional Fund Advisors LP lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 15.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 484,431 shares of the companyOctober 9, 2024 | marketbeat.comCubist Systematic Strategies LLC Has $80,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Cubist Systematic Strategies LLC trimmed its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 91.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,597 shares of the company's stock after selling 71October 8, 2024 | marketbeat.comSquarepoint Ops LLC Acquires 74,452 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Squarepoint Ops LLC grew its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 143.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,389 shares of the company's stoOctober 5, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.1%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.1%October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Trims Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Point72 Asset Management L.P. lessened its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 76.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 358,945 shares of the company's stock after selling 1,168,155 sOctober 3, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued aOctober 2, 2024 | marketbeat.comY-mAbs to Participate in Upcoming Investor Conferences in OctoberOctober 1, 2024 | globenewswire.comWhile shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunateSeptember 25, 2024 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7%Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 4.7%September 23, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $389,100.00 in StockSeptember 18, 2024 | insidertrades.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 8.1%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 8.1%September 17, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 6.9% Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.9%September 16, 2024 | marketbeat.comAcadian Asset Management LLC Sells 279,139 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Acadian Asset Management LLC decreased its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 46.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 323,175 shares of the company's sSeptember 13, 2024 | marketbeat.comNavigating 8 Analyst Ratings For Y-mAbs TherapeuticsSeptember 11, 2024 | nasdaq.comY-mAbs Therapeutics' (YMAB) Outperform Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday.September 10, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday.September 9, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from AnalystsShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have asSeptember 7, 2024 | marketbeat.comY-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchSeptember 6, 2024 | globenewswire.comY-mAbs to Participate in Upcoming Investor Conferences in SeptemberSeptember 3, 2024 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 5.5% Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 5.5%August 29, 2024 | marketbeat.com Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.340.56▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼133▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRSN News Today AMRN News Today HRTX News Today GBIO News Today AUPH News Today LBPH News Today AMPH News Today AKRO News Today NAMS News Today SRRK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
